HC Wainwright Reiterates "Buy" Rating for Palvella Therapeutics (NASDAQ:PVLA)

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 price objective on the stock. HC Wainwright's target price points to a potential upside of 58.47% from the stock's previous close. HC Wainwright also issued estimates for Palvella Therapeutics' Q1 2025 earnings at ($3.56) EPS, Q1 2025 earnings at ($3.56) EPS, Q2 2025 earnings at ($3.79) EPS, Q2 2025 earnings at ($3.79) EPS, Q3 2025 earnings at ($4.05) EPS, Q4 2025 earnings at ($4.33) EPS, Q4 2025 earnings at ($4.33) EPS, FY2025 earnings at ($15.73) EPS, FY2025 earnings at ($15.73) EPS, FY2026 earnings at ($12.67) EPS, FY2026 earnings at ($12.67) EPS, FY2027 earnings at ($13.80) EPS, FY2027 earnings at ($13.80) EPS, FY2028 earnings at ($8.72) EPS, FY2028 earnings at ($8.72) EPS and FY2029 earnings at ($5.23) EPS.

Several other research firms have also recently weighed in on PVLA. Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 price target on the stock. Scotiabank initiated coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price target on the stock. Jones Trading assumed coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a "buy" rating and a $45.00 target price for the company. Finally, Cantor Fitzgerald started coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an "overweight" rating on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $43.50.

Remove Ads

Palvella Therapeutics Stock Performance

Shares of PVLA traded down $0.45 during midday trading on Tuesday, hitting $23.98. 218,861 shares of the company traded hands, compared to its average volume of 65,732. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27. The firm has a market cap of $269.08 million, a price-to-earnings ratio of -1.98 and a beta of 0.54. The stock's 50-day moving average is $21.25.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC purchased a new position in shares of Palvella Therapeutics in the fourth quarter worth about $8,574,000. BVF Inc. IL purchased a new position in Palvella Therapeutics in the 4th quarter worth approximately $8,359,000. Samsara BioCapital LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $8,154,000. Frazier Life Sciences Management L.P. bought a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $7,847,000. Finally, Adams Street Partners LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter valued at approximately $4,916,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.